Advanced Regenerative Manufacturing Institute Inc.

Manchester, NH Doing business as Armi

UEI
LA8CKGSANQG7
CAGE
7P8A2
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Non-Profit Organization
Entity structure
Corporate Entity (Tax Exempt)
Corporate family
SAM.gov registration date
Physical address
400 Commercial St, Manchester, NH 03101, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $10,285,993
FY2025 $47,181
FY2024 $1,566,897
FY2023 $10,360,875

Top agencies by obligations

Rank Agency Obligated, FY2026–FY2027 Share
1 Department of Health and Human Services $10,285,993

Contract awards

Grant awards

Latest 5 listed here. See the rest on GovTribe.

Grant subawards

Prime recipient Prime award Amount Awarded
Case Western Reserve University Subaward between CWRU and Advanced Regenerative Manufacturing Institute. P41EB021911 $143,508
Not on record Upscaling MII Solutions: Advanced Manufacturing Competency Framework Creation W911NF1730004 $80,000
Southern New Hampshire University Scale pilot approach and apprenticeship program and BioTek program 017915304 $1,449,817
Case Western Reserve University Subaward between Advanced Regenerative Manufacturing Institute and CWRU. P41EB021911 $143,495
Bioindustrial Manufacturing And Design Ecosystem ADP27 FA86502125028 $214,229

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

About the company

Advanced Regenerative Manufacturing Institute Inc., doing business as Armi, a tax-exempt non-profit organization based in Manchester, New Hampshire, performs independent validation and verification services, biofabrication manufacturing standardization, and cluster-coordination work for federal health agencies as a prime recipient of federal grants and contracts. Armi competes full-and-open across nine distinct federal customer agencies, with no set-aside designation; the organization operates as a prime on 74% of recent awards and carries a named for-profit subsidiary, Armi Bioindustries Corp, certified as a Small Disadvantaged Business.

Armi's capability portfolio centers on regenerative medicine manufacturing, cell and tissue engineering standardization, and biofabrication infrastructure development. Its recent prime contract work includes a $17.87 million definitive contract awarded by the National Institutes of Health on June 1, 2026 for independent validation and verification services supporting the ARPA-H Resilient Extended Automatic Cell Therapies (REACT) program—scaling manufacturing capability for two engineered cell therapy devices, the "Living Pharmacy" and "Living Sentinel," through November 2028 on a time-and-materials basis. The Food and Drug Administration awarded Armi a $2.24 million definitive contract in September 2024 for the Biofab Foundry initiative, developing a scalable closed-system automated medical product manufacturing platform, extended through September 2027 under a cost-no-fee structure. Armi also received a $1.2 million project grant from the National Institute of Standards and Technology in October 2024 to develop standardized infrastructure and quality-by-design approaches for biofabrication assay development, specifically improving the Glucose Stimulated Insulin Secretion (GSIS) assay for automation and reproducibility across cell and tissue-based assays.

Customer concentration sits heavily with the Department of Health and Human Services, which anchors the dollar value—the HHS Office of the Assistant Secretary for Preparedness and Response (two awards, $29.3 million combined potential value) and HHS National Institutes of Health ($17.9 million combined potential value) together represent the largest contract tranches. The Department of Commerce Economic Development Administration dominates by award count (8 awards), funding cluster-development and regional biofabrication ecosystem work across multiple project grants totaling approximately $45 million for establishing Southern New Hampshire as a biomanufacturing hub. The top five customer agencies by combined potential value account for 100% of awards in the source dataset. A single recompete exposure—the FDA Biofab Foundry contract for $2.2 million—reaches ultimate completion within the next twenty-four months.

Armi's grant footprint is substantial. As prime recipient, the organization has received multiple Economic Development Administration project grants supporting the Biofabrication Cluster led by the City of Manchester, including awards of $31.2 million, $5.178 million, $4.67 million, and $4.2 million (all September 2022), alongside a $6.9 million cooperative agreement from HHS Office of the Assistant Secretary for Preparedness and Response (September 2022, extended through September 2025) to establish an ARMI Health Tech Hub program for bilateral U.S.-Israeli health technology and health security. Armi received a National Science Foundation project grant in March 2023 to host the NSF-ARMI BioFabUSA workshop on advanced tissue manufacturing standardization. As a sub-recipient, Armi has received grant sub-awards from Southern New Hampshire University (January 2025, scaling apprenticeship and pilot programs; August 2023, transportation equity study management), Case Western Reserve University (January 2025), and Bioindustrial Manufacturing And Design Ecosystem (September 2024).

Service Contract Inventory captures $6.3 million in SCI-reportable invoiced revenue in FY2024 across 0.1 FTEs (contract-level)—a minimal slice of Armi's federal footprint, reflecting that the bulk of recent work flows through grants and definitive contracts rather than service-contract vehicles. Government-paid hourly rates on SCI-reportable prime work run at a median of $2,014.95/hr. Across SCI-reportable prime contracts, subcontractors account for approximately 24% of contractor hours, with two named subcontractors reported; Armi's sub-engagement rate suggests modest reliance on subcontractor capacity relative to direct delivery. Activity has grown from two awards in 2023 to six in 2024, with a combined potential value of $49.4 million across 19 total awards, though obligations ($131.8 million) exceed potential value by 267%, indicating drawdowns against multi-year grant tranches and contract task order execution against higher ceilings than the source's potential-value snapshot captures.

Quick answers

Is Advanced Regenerative Manufacturing Institute Inc. registered in SAM.gov?

Yes. Advanced Regenerative Manufacturing Institute Inc.'s SAM.gov registration is active through March 13, 2027.

How much has Advanced Regenerative Manufacturing Institute Inc. received in federal contracts?

Federal contracts obligated $47,181 to Advanced Regenerative Manufacturing Institute Inc. in fiscal year 2025 and $22,260,946 in fiscal years 2023 through 2027.

What is Advanced Regenerative Manufacturing Institute Inc.'s most recent federal award?

Advanced Regenerative Manufacturing Institute Inc.'s most recent federal contract award is Independent validation and verification (IV & v) services (75N99226C00001), from National Institutes of Health, on June 1, 2026.

On GovTribe

See Advanced Regenerative Manufacturing Institute Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Subcontracting relationships
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors